This post was originally published on this site

Akrevia Therapeutics is on a mission to make immunotherapies safer. The startup, based in the LabCentral incubator in Cambridge, Mass., is working on drug candidates that act much like therapies that are already on the market, including Bristol Myers-Squibb’s Yervoy and Clinigen’s Proleukin. It’s hoping it can find new drugs that mimic those effects butRead More »

The post Startup Spotlight: Akrevia Therapeutics eyes safer immunotherapies appeared first on Atlas Venture.